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Weekly epirubicin for breast cancer with liver metastases and abnormal
liver biochemistry
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Summary Thirty-six consecutive patients with breast cancer and liver metastases with abnormal liver
biochemistry were treated with epirubicin 25 mg m-2 i.v. weekly. No dose modification was made for
abnormal liver biochemistry, but dose intensity was adjusted by delaying treatment according to myelosupp-
ression. The UICC overall response rate according to UICC criteria was 11/36 (30%) and median response
duration was 27 weeks. Liver biochemistry improved in a further seven patients. Treatment was well tolerated.
Epirubicin given in this way is effective in patients with breast cancer and liver metastases. An initial
deterioration in liver biochemistry may occur before there is a response to epirubicin.
Liver metastases are common in patients with advanced
breast cancer. The prognosis is worse for these patients than
after recurrence in either soft tissue (Fentiman et al., 1986) or
bone (Coleman & Rubens, 1987). Survival is particularly
poor in patients with liver metastases and abnormal liver
biochemistry (Swenerton et al., 1979; Zinser et al., 1987; S.M.
O'Reilly, in preparation). The treatment of patients with liver
metastases is difficult. Responses to endocrine therapy are
uncommon (Australia & New Zealand Breast Cancer Trials
Group, 1986). The administration of chemotherapy may be
complicated by the liver's role in both cytotoxic drug activa-
tion, as for cyclophosphamide (Bagley et al., 1973), and
metabolism, as with doxorubicin (Benjamin et al., 1974).
Moreover, although anthracyclines are the most active single
agents in patients with breast cancer (Steiner et al., 1983),
toxicity can be severe in patients with impaired liver function
and reduced hepatic drug clearance (Benjamin et al., 1974).
Epirubicin (4'-epidoxorubicin) is a new anthracycline,
structurally related to doxorubicin and with similar activity
in patients with advanced breast cancer (Brambilla et al.,
1986). It is eliminated more rapidly than doxorubicin
(Camaggi et al., 1988) and, at equimolar doses, is less toxic
than doxorubicin (Brambilla et al., 1986). We report our
experience of the efficacy and toxicity of epirubicin in
patients with breast cancer and liver metastases who have
abnormal liver biochemistry.
Patients received a low dose of epirubicin on a weekly
schedule, with the aim of giving a high dose intensity whilst
minimising toxicity.
Patients and methods
Thirty-six patients with histologically proven breast cancer,
progressive liver metastases and abnormal liver biochemistry
were entered into this phase II study. Eligible patients had
liver metastases confirmed by technetium sulphur colloid
radionuclide scan or ultrasound scan, and either a serum
aspartate transaminase (AST) more than twice the upper
limit of normal or an elevated serum bilirubin. Four patients
had received previous adjuvant chemotherapy, three with a
combination of cyclophosphamide, methotrexate and 5-
fluorouracil (CMF) and one with L-PAM. A further four
patients had undergone earlier chemotherapy with CMF for
advanced breast cancer. Patients who had received previous
anthracycline treatment were excluded from the study.
Epirubicin 25 mg m-2 intravenously was given every 7
days. Liver biochemistry tests were repeated weekly but dose
adjustments were not made for raised serum transaminases
or bilirubin. However, chemotherapy was given only if the
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white blood cell count was above 2.0 x IO' 1' and platelet
count above 70 x 10' 1-l. If the blood count fell below these
levels, treatment was delayed until these counts were reached.
With each course of chemotherapy patients received
antiemetics, in most cases metoclopramide (20 mg i.v.) either
alone or with dexamethasone (5-20 mg i.v.).
In these patients, the liver was the dominant site ofdisease.
Objective responses were assessed therefore by UICC criteria
for liver metastases (Hayward et al., 1977). A complete
remission (CR) was defined as disappearance of all evidence
of hepatic metastases on repeat liver scan, clinical examina-
tion and serum biochemistry. A partial remission (PR)
required at least a 50% reduction in hepatic metastases on
liver scan and a 50% or greater decrease in palpable
hepatomegaly below the costal margin. In an attempt to
evaluate the importance of changes in liver biochemistry, we
have defined patients with a greater than 50% reduction in
abnormalities of serum bilirubin or AST, but stable disease
on UICC criteria, as biochemical responders.
It was planned that all patients receive a minimum of six
and a maximum of 12 cycles of weekly epirubicin. If there
was disease progression after six cycles, chemotherapy was
stopped. Patients with responding or stable disease according
to UICC criteria continued weekly epirubicin for a further
six cycles unless unacceptable toxicity or disease progression
were documented during this period. Patients who were in
remission after 12 cycles, generally stopped chemotherapy
and were observed without treatment. These patients were
eligible for further chemotherapy, including epirubicin, at
relapse.
Treatment toxicity was graded by the WHO classification
(Miller et al., 1981). Survival was measured from the date of
first epirubicin treatment to death, and progression-free inter-
val from the date of first epirubicin treatment to the date of
progression.
Results
Patient characteristics on entry to the study are shown in
Table I. All 36 patients were assessable for response to
chemotherapy, with a median follow-up of 38 weeks. They
received a median of eight initial weekly epirubicin
treatments (range 1-15) and 15 patients completed 12
courses of chemotherapy. Fifteen patients had a raised
bilirubin on entry and the median AST was four times
greater than the upper limit of the laboratory's normal range.
The serum alkaline phophatase was raised in all patients, but
24 patients also had bone metastases. Alkaline phosphatase
was therefore not used to diagnose liver metastases or to
monitor response to treatment.
One patient achieved a complete remission (CR) and 10 a
partial remission (PR) on weekly epirubicin. The responders
included four of the 12 patients who were jaundiced before
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Table I Patient characteristics on entry to the study
No. of patients
Median age
Histology
Infiltrating ductal
Infiltrating lobular
Unknown
Receptor status at initial diagnosis
ER unknown
positive
negative
PR unknown
positive
negative
Previous chemotherapy
Previous endocrine therapy
Menstrual status
Premenopausal
1-5 years post-menopausal
> 5 years post-menopausal
UICC performance status
0
l
2
3
Sites of assessable extrahepatic metastases
Bone
Lymphatic
Skin
Lung
Pleura
Breast
Clinical signs of liver metastases
Jaundice
Ascites
Hepatomegaly
Median AST
(normal < 34)
Median bilirubin
(normal < 17)
Imaging technique
Radionuclide scan
Ultrasound
CT
36
54 years (range 26-79)
28
2
6
17
15 (79% of known
patients)
4 (21%)
16
10 (50%)
10 (50%)
8 (4 as adjuvant)
24
9
5
22
5 patients
10
15
6
23
8
6
3
3
4
12
3
29
151 (72-392)
19 (7-287)
19
16
l
chemotherapy. All 11 patients who achieved an objective res-
ponse (UICC) had improvement of liver biochemistry. Seven
other patients had a biochemical response, but either had stable
disease on repeat liver scan (four patients) or the scan was not
repeated (three patients). In two of these patients, liver
biochemistry returned to normal during chemotherapy, but the
metastases were unchanged on repeat liver scan.
The objective response rate for liver metastases was 11/36
(30%, with 95% confidence limits of 15-45%) according to
UICC criteria, and 18/36 (50%, with 95% confidence limits
of 33-67%) if patients with a biochemical response are
included. Responses were also observed in soft tissue, bone
and other visceral metastases. Only two patients in whom
liver metastases failed to respond to epirubicin achieved a
response at other metastatic sites of disease. No patient who
responded in the liver showed progression of disease
elsewhere. Median progression free interval in the 11 UICC
responders was 27 weeks (range 8-40), and in the seven
biochemical responders 22 weeks (range 7-25). All patients
who responded according to UICC criteria, and the
biochemical responders, had improvement of symptoms in-
cluding reduction in nausea, anorexia, hepatic pain and/or
improvement in performance status.
During the first month of treatment, serum bilirubin or
AST rose by at least 25% in seven of the 18 responders. Six
of these seven patients had a raised serum bilirubin before
chemotherapy. As chemotherapy continued liver biochemis-
try subsequently improved, and by 6 weeks these patients
could clearly be distinguished from those with progressive
disease in whom there was a steady deterioration. Figure I
shows the two patterns of serial liver biochemistry we
observed in patients who achieved a UICC response.
a
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Figure 1 Serial AST and bilirubin - - in (a) a
responding patient with steady improvement in liver biochemis-
try, (b) a patient with initial deterioration in liver biochemistry
who later responded.
Eleven patients received further chemotherapy at relapse.
Six of these patients were treated again with epirubicin and
two achieved a second response. Four patients were treated
with a combination of cyclophosphamide, methotrexate and
5-fluoruoracil and one with cyclophosphamide alone, but
none responded.
Median survival for all patients was 16 weeks (range 1-54)
(Figure 2). There were no deaths directly related to
chemotherapy but two patients died without evidence of
disease progression, one from gastrointestinal haemorrhage
and one with a pulmonary embolism which was confirmed at
post-mortem. Twelve patients died within 6 weeks of starting
chemotherapy. Ten of these 12 patients had had a 4-fold or
greater elevation in initial AST which strongly predicted for
early death (P = 0.025, Fisher's exact test). Survival for the
biochemical responders was similar to that for UICC res-
ponders (P = 0.14, log rank test), and was significantly better
than for patients with progressive disease (P = 0.03, log rank
test).
All patients were evaluable for toxicity. Treatment was
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Figure 2 Survival - all patients.
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generally tolerated well. Despite being offere.d scalp cooling,
all patients who received six or more courses of epirubicin
developed WHO grade 2 or 3 alopecia. Gastrointestinal tox-
icity was mild, with grade 3 stomatitis in two patients and
grade 4 vomiting in one patient. Myelosuppression delayed
34 of 263 weekly treatments (13%). Treatment delays occur-
red in four of the 15 patients with a raised bilirubin before
starting chemotherapy and in six of 21 patients who initially
had a normal bilirubin. There was no grade 4 haematological
toxicity, and there were no episodes of septicaemia.
Discussion
The prognosis for breast cancer patients with liver metastases
is poor. Treatment is palliative and the aim must be to
combine maximum efficacy with acceptable toxicity. Dox-
orubicin is the most active single agent in breast cancer
(Steiner et al., 1983) and is more effective at high
(70mgm2) than low (35 mgm2) doses (Carmo-Pereira et
al., 1987). However, because anthracyclines are metabolised
by the liver, elimination is delayed in patients with liver
dysfunction (Benjamin et al., 1984). Unfortunately there is
only a poor correlation between conventional liver
biochemical tests and anthracycline metabolism (Preiss et al.,
1987) and dose adjustments based on these tests are empirical
(Benjamin et al., 1974). Epirubicin is also metabolised prin-
cipally by the liver (Camaggi et al., 1982), and the manufac-
turers recommend dose reduction in patients with moderate
or severe liver impairment as defined by raised serum
bilirubin or bromsulphthalein clearance. In this study such
dose modifications were not made. We adjusted dose inten-
sity according to myelosuppression; in this way any effect of
decreased epirubicin clearance due to impaired liver function
led to a delay in treatment and reduction in dose intensity.
Few studies have been directed specifically at breast cancer
patients with liver metastases (Zinser et al., 1987; O'Reilly et
al., 1989). The majority of reports of chemotherapy in such
patients have been derived from larger studies of patients
with metastatic disease in a varity of sites. A review of these
trials by Kemeny (1983) showed a response rate for liver
metastases of between 30 and 75%. These results are not,
however, directly comparable with those in the current study.
Details of disturbances in liver biochemistry were not given,
although abnormalities of liver biochemistry confer a poor
prognosis (Swenerton et al., 1979; Zinser et al., 1987;
O'Reilly et al., 1989). Indeed, many studies have specifically
excluded patients with abnormal liver biochemistry although
at least a third of breast cancer patients have a 2-fold or
greater elevation in AST at the time of diagnosis of liver
metastases (Zinser et al., 1987; S.M. O'Reilly, in prepara-
tion). It is important to evaluate treatment regimens in this
group of patients.
We have treated a clearly defined group of breast cancer
patients with liver metastases and abnormal liver biochemis-
try using a single drug, epirubicin, given weekly. Our results
show that in these patients epirubicin given in this way
achieves a response rate of 30% according to UICC criteria.
This rises to 50% if patients with a biochemical response are
included, and these patients had a significantly better prog-
nosis than patients with progressive disease, suggesting that
improved liver biochemistry may be a useful additional
measure of response to chemotherapy. Moreover, seven of
the 25 patients (28%) whose liver biochemistry deteriorated
during the first month of treatment subsequently achieved
either a response according to UICC criteria or a
biochemical response. This may simply reflect a continuing
deterioration in liver biochemistry before treatment has time
to take effect, or a hepatotoxic effect of epirubicin in patients
with severely disturbed liver function. Transient abnor-
malities of liver biochemistry have also been reported in
patients with breast cancer receiving an adriamycin, 5-
fluorouracil and cyclophosphamide regimen (Larroquette et
al., 1986), and patients with hepatocellular carcinoma treated
with mitoxantrone (Yoshida et al., 1988). Whatever the
mechanism ofthe initial deterioration in liver biochemistry, it
is important to note that, although liver biochemistry may be
a useful indicator of response to chemotherapy, it is not a
reliable measure of progression during the first few weeks of
treatment. Chemotherapy should be continued for at least 6
weeks before response is assessed, as an initial deterioration
in liver biochemistry does not necessarily indicate disease
progression.
We adjusted dose intensity of epirubicin according to the
severity of myelosuppression alone, regardless of liver
biochemistry, and found no difference in the number of
treatment delays between patients with normal or raised
bilirubin. A conventional dose reduction might have exposed
some patients to suboptimal chemotherapy and others to
unacceptable toxicity. Comparison with historical results
from Guy's Breast Unit suggests that epirubicin given in this
way is more active than either mitoxantrone (O'Reilly et al.,
1989) or other chemotherapy (predominantly adriamycin at
3-weekly intervals or a combination of cyclophosphamide,
methotrexate and 5-fluorouracil) in this group of patients
(S.M. O'Reilly, in preparation). However, median survival in
this study was only 16 weeks and, although responders
gained symptomatic benefit, it remains uncertain whether
chemotherapy improves survival in patients with liver meta-
stases. Nevertheless, it seems likely that in this study
epirubicin delayed death in some patients.
We conclude that patients with breast cancer and liver
metastases who have abnormal biochemistry can usefully be
treated with weekly epirubicin 25 mg m-2, adjusting dose
intensity according to myelosuppression. This treatment is
tolerated well. However, an initial deterioration in liver
biochemistry may occur before there is a response to
epirubicin.
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